Retinalgenix Technologies INC
Market Movers (8-K)
OID
RetinalGenix Technologies Inc. announced the resignation of its independent auditor, Liebman Hymowitz, LLP, effective July 13, 2026, and the appointment of Vilki & Co. as its new auditor.
OID
RetinalGenix Technologies Inc. announced the immediate resignation of its Chief Financial Officer, Michael Cory Zwerling, effective March 22, 2026.
Worse than expected
OID
RetinalGenix Technologies Inc. has amended its warrant agreement with Sanovas Ophthalmology, LLC, restricting the exercise of warrants until at least February 1, 2030, or three years after a potential uplisting to Nasdaq or NYSE American.
Delay expected
OID
A Delaware court order has voided 3 million shares of RetinalGenix Technologies Inc.'s Series F Preferred Stock previously issued to Halo Management LLC.
Quarterly Earnings (10-Q)
OID
RetinalGenix Technologies reports a net loss of $590,489 for Q1 2026 while highlighting ongoing liquidity challenges and a going concern warning.
Capital raise
OID
RetinalGenix Technologies Inc. reported a reduced net loss for Q3 2025, but faces significant liquidity challenges and a going concern warning, necessitating substantial additional capital.
Worse than expected
Delay expected
Capital raise
OID
RetinalGenix Technologies Inc. reported continued significant net losses and a critical cash shortage for Q2 2025, raising substantial doubt about its ability to continue as a going concern without immediate capital infusion.
Worse than expected
Delay expected
Capital raise
OID
RetinalGenix Technologies Inc. reported a net loss of $1.24 million for the first half of 2025, with minimal cash and substantial doubt about its ability to continue as a going concern.
Worse than expected
Delay expected
Capital raise
OID
RetinalGenix Technologies reports no revenue and a net loss of $587,259 for Q1 2025, with substantial doubt about its ability to continue as a going concern.
Capital raise
Worse than expected
OID
RetinalGenix Technologies reports a net loss of $3.45 million for the nine months ended September 30, 2024, and expresses substantial doubt about its ability to continue as a going concern.
Worse than expected
Capital raise
Annual Reports (10-K)
OID
RetinalGenix Technologies Inc. outlines its strategy to prevent vision loss through innovative devices and drug development while acknowledging substantial financial challenges and a going concern uncertainty.
Capital raise
Worse than expected
OID
RetinalGenix Technologies Inc. has filed its annual 10-K report, detailing its progress in developing medical devices and therapeutic candidates for ophthalmic and systemic diseases, while also highlighting its financial position and future capital needs.
Delay expected
Capital raise
Worse than expected